Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Medical Ikkou Group Co.,Ltd. (3353.T)
Tsu, JP
Medical Ikkou Group Co.,Ltd. is a Japanese enterprise primarily known for managing dispensing pharmacies across the nation. Beyond its extensive pharmacy operations, the company diversified its activities to include the management of various care facilities, such as nursing homes, outpatient nursing centers, and home-visit nursing care services. Its business portfolio also encompasses the wholesale of generic pharmaceuticals and real estate property rentals. Furthermore, the group is active in financial investments, including stakes in both listed and unlisted securities, and participates in merger and acquisition activities. The company currently oversees 93 dispensing pharmacy locations. Established in 1980, Medical Ikkou Group is headquartered in Tsu, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.96% | +0.18% | -3.24% | -9.93% | +1.70% | -5.47% | +17.44% | +22.03% | -0.65% | +15.91% | +213.94% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Conglomerates: +6.1%+13.6% ★ Q2'26: +5.7% (vs Q2'25)
-
EPS growth Conglomerates: +16.9%+12.4% Q2'26: +45.4% (vs Q2'25)
-
FCF margin FCF growth · Conglomerates: +35.9%+0.8% ★ Q2'26: +0.0% (vs Q2'25)
-
EBIT margin Conglomerates: +9.0%+3.3% Q2'26: +3.1% (vs Q2'25)
-
ROIC Conglomerates: +4.7%+5.7% ★ Q2'26: +6.6% (vs Q2'25)
-
Share dilution Conglomerates: +0.0%+0.1% Q2'26: +0.1% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Conglomerates: 1.28×3.94× Q2'26: 3.82× (vs Q2'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Feb 2018 actual |
|---|---|
| Revenue |
30.91B
est: 31.10B (-0.6%)
|
| EBITDA |
2.19B
est: 2.05B (+6.9%)
|
| EBIT |
1.41B
est: 1.35B (+4.2%)
|
| Net Income |
1.24B
est: 961.69M (+28.8%)
|
| SGA |
1.69B
est: 1.88B (-10.1%)
|
| EPS |
323.12
est: 255.75 (+26.3%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-05-01 | A | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 1/5 | 4/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kanichi Eguchi | Senior Executive Officer | — | — |
| Katsumi Kojima | Senior Executive Officer | — | male |
| Katsutaka | Senior Executive Officer & Director of Human Resources & Management | — | — |
| Kunihiko Toyama | GM of Systems, MD & Kanto Branch and Director | — | male |
| Kyosuke Oda | Senior Executive Officer, Head of Accounting, Finance & IR Dept. | — | — |
| Ryuji Fukushima | Senior Executive Officer & GM of Group Audit & Management Office | — | — |
| Satoshi Notsu | Senior Executive Officer | — | — |
| Toshiharu Sakurai | Senior MD of General Management & Representative Director | — | male |
| Toshihisa Minamino | President, Group Chief Executive Officer & Representative Director | — | male |
| Yoshiyuki Adachi | Senior Executive Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3353.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
